Pearce Samantha sold $1.6M of JAZZ
Pearce Samantha (EVP, Chief Commercial Officer) sold 6,907 shares of Jazz Pharmaceuticals plc (JAZZ) at $235.41 ($1.63M total) on 2026-05-28.
How this was made
The 30-second read
Why it matters
The disclosure provides incremental sentiment information but does not change Jazz’s fundamentals or near-term catalyst calendar on its own.
Market read
Traders may briefly reassess sentiment around JAZZ, but the event is unlikely to drive a sustained repricing without corroborating news.
What to watch
No 10b5-1 plan is indicated, so traders may over-interpret; also, Form 4 timing reflects disclosure lag, not the exact market reaction day.
Background
SEC Form 4 reports insider transactions; this filing covers an open-market sale by Jazz’s EVP/Chief Commercial Officer.
Ticker impact
Jazz Pharmaceuticals disclosed an open-market sale by its EVP/Chief Commercial Officer for $1.63M of shares.
Low near-term impact; any move is likely noise unless accompanied by other news.
This is a Form 4 insider transaction with no 10b5-1 plan stated and no accompanying operational/clinical update.
Market effects
Minimal; single-company insider transaction without sector-wide read-through.
None.
None.
Counterpoint
The sale may be routine liquidity/portfolio rebalancing rather than a bearish view, especially given the modest size versus typical institutional float.
Key entities
- issuerJazz Pharmaceuticals plc
Subject of the Form 4 insider sale by an executive officer.
- insiderSamantha Pearce
EVP, Chief Commercial Officer who sold 6,907 shares at ~$235.41.
